Add BrightSurf on Google Email

Immunotherapy for glioblastoma well tolerated; survival gains observed

A phase one study of 11 patients with glioblastoma who received injections of an investigational vaccine therapy and an approved chemotherapy showed the combination to be well tolerated while also resulting in unexpectedly significant survival increases. The researchers found that the combination significantly slowed the progression of...

SourceDuke University Medical Center·JournalClinical Cancer Research·DateApr 14, 2017

How to mix the perfect cocktail

Researchers have developed a method to predict interactions among multiple drugs in combination, bypassing the need for astronomical measurements. The new mathematical model enables scientists to identify optimal blends for chemotherapy cocktails and potentially aid personalized medicine.

SourceWeizmann Institute of Science·JournalProceedings of the National Academy of Sciences·DateApr 9, 2017

A multidrug efflux pump in motion

A multidrug efflux pump in motion: Researchers have mapped the conformational changes that occur in P-glycoprotein, a protein notorious for pumping chemotherapeutic drugs out of cancer cells. This study sheds light on how P-glycoprotein binds and transports molecules, with potential implications for developing new treatments.

Available drug may protect ovaries and fertility from damage by chemotherapies

A study found that the drug everolimus protects ovaries from cyclophosphamide, a common chemotherapy used against breast cancer, which depletes egg cells needed to achieve pregnancy. Female mice treated with everolimus and chemotherapy had more than twice as many offspring as those treated with chemotherapy alone.

SourceNYU Langone Health / NYU Grossman School of Medicine·JournalProceedings of the National Academy of Sciences·DateMar 6, 2017

Monoclonal antibody drug superior to chemotherapy for advanced acute lymphoblastic leukemia

A Phase III clinical trial revealed that blinatumomab significantly increased overall survival and remission rates compared to standard chemotherapy in patients with advanced acute lymphoblastic leukemia. The study showed a median survival of 7.7 months for those treated with blinatumomab versus four months for those on chemotherapy.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNew England Journal of Medicine·DateMar 1, 2017

Liver tumor growth in mice slowed with new chemo-immunotherapy treatment

Researchers developed a new treatment combining chemotherapy and immunotherapy to slow liver tumor growth in mice, with tumors growing 11 times smaller than in control groups. The study suggests that this approach could be translated to benefit patients with hepatocellular cancer, potentially extending and improving their quality of life.

SourceUniversity of Missouri-Columbia·JournalJournal of Hepatology·DateFeb 28, 2017

MS treatment that 'resets' immune system may halt disease progression for at least 5 years

A type of autologous hematopoietic stem cell transplantation (AHSCT) has been shown to slow or stop MS disease progression for up to five years in nearly half of patients, with significant benefits seen in younger patients and those with relapsing-remitting MS. However, the treatment carries a small risk of death and is not suitable fo...

SourceImperial College London·JournalJAMA Neurology·DateFeb 20, 2017

Novel combination therapy overcomes difficult-to-treat form of antibiotic resistance

Researchers have discovered a novel combination therapy that successfully treats infections caused by a pernicious form of antibiotic resistance. The treatment regimen, which includes ceftazidime/avibactam and aztreonam, overcomes the resistance caused by metallo-ß-lactamases, a growing global public health problem.

SourceAmerican Society for Microbiology·JournalAntimicrobial Agents and Chemotherapy·DateFeb 6, 2017

More individual therapy for blood cancer patients

Researchers from Goethe University Frankfurt discovered a novel biomarker, SAMHD1, that enables accurate prediction of therapy responders and non-responders in acute myeloid leukaemia (AML) patients. This biomarker can guide cytarabine-based chemotherapies to only those patients likely to respond, sparing others from toxic side effects.

SourceGoethe University Frankfurt·JournalNature Medicine·DateJan 10, 2017